concentrations of factor VII and protein C decrease rapidly because of their short half lives. The further decrease in the already low protein C activity leads to thrombosis in the microvasculature, which appears to be the site of protein C activation.15 The microthrombosis is followed by infarction and haemorrhage, enhanced by the lowered factor VII concentration. As haemorrhagic infarction of the chorioid plexus with intraventricular haemorrhage is not a rare finding in intracranial venous thrombosis1 17 this mechanism may have started the intraventricular bleeding, and the subsequent excessive coumarin effect may have contributed to its profuse nature.
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Protein C and the development of skin necrosis during anticoagulant therapy. Thromb Haemost 1983;49:244. 13 Samama M, Horellou MH, Soria J, Conard clinic. Endogenous insulin secretion for all subjects was assessed by measurement of fasting plasma C peptide concentrations and the C peptide response to intravenous glucagon.5 All patients had normal liver and renal function and normal haematological profiles. Fourteen diabetic patients were further investigated with 25 serial blood specimens collected over a single 24 hour period. The mean plasma glucose concentration and mean amplitude of glycaemic excursion' were derived for each patient from these measurements. Table I summarises the clinical details of all the subjects. Informed consent was obtained from all participants at the outset, and the study was approved by the Auckland Hospital's human ethics committee. Blood specimens were obtained from all subjects after an eight hour overnight fast and before the administration of insulin in the diabetic group. Serum or plasma samples were stored at -20°C for glucose, insulin, and fructosamine estimation, and at -70°C for C peptide analysis. Haemolysates were prepared without dialysis and stored in liquid nitrogen for HbA1c analysis. All samples were tested within 24 hours of being thawed.
Fructosamine assay-Serum fructosamine4 was assayed with an automated discrete analyser (Abbott Laboratories, Chicago). The reagent was carbonate buffer pH (OilM) containing nitro blue tetrazolium chloride (0-25mM), and the standards were 1-deoxy, 1-morpholinofructose9 in human albumin (40 g/l) (Commonwealth Serum Laboratories). The within batch assay imprecision was 2-9% and between batch assay imprecision 2-9%.
Other tests-Glucose concentrations were determined using a hexokinase and glucose-6-phosphate dehydrogenase technique.10 Within batch imprecision of the assay was 3 0% and between batch imprecision 15%/. HbAle concentrations were determined by isoelectric focusing1' using commercial polyacrylamide gels and a laser densitometer (LKB, Bromma, Sweden). Within batch imprecision was 4% and between batch imprecision 7%. Plasma C peptide value was measured using a commercial radioimmunoassay kit (Novo, Copenhagen). Plasma free insulin concentrations were measured by radioimmunoassay using antisera against purified porcine insulin12 after extraction with polyethylene glycol.13 Statistical Figure 1 compares these values in the diabetic and non-diabetic subjects.
Comparison with other indices of diabetic control-Fasting serum fructosamine concentrations in diabetic patients correlated significantly with mean plasma glucose values obtained from multiple blood samples over 24 hours, fasting plasma glucose values, but not mean amplitude of glycaemic excursion. The latter is a measure of within day glucose instability and emphasises the major meal related glucose swings by eliminating minor glucose excursions-that is, those within one standard deviation of the daily mean blood glucose concentration.' Table II Relation to plasma C peptide concentrations-There was a highly significant negative correlation between serum fructosamine and fasting plasma C peptide concentrations (r=-0-81; p<0-001) in the. 42 diabetic and 30 non-diabetic subjects (fig 3) . Two outliers were identified in the statistical analysis." Case 1 was a 17 year old youth with needle phobia who tended to neglect his daily injections, and case 2 was a 22 year old woman who frequently suffered mild subclinical hypoglycaemia (see figure 2 ) and subsequently collapsed, requiring resuscitation in the hospital casualty department. The correlation between fructosamine and fasting plasma free insulin concentrations in the same subjects was not significant (r=0 12; p>010) (not shown).
Discussion
Critical appraisal discloses problems with most of the tradi- Conversion: SI to traditional units-Fructosamine: 1 mmol/l 25 mg/100 ml. C peptide: 1 pmol/I13-02 pg/ml.
We find that the main practical advantages of the fructosamine assay compared with HbA,, estimation are the use of unmodified serum samples, the ease of analysis and precision achieved with automated laboratory equipment, and the suitability of commercial quality control sera to control the method. By contrast, the accurate measurement of HbA,, is technically 66 0.
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demanding and requires special precautions to ensure stability of specimens."5 16 The assay is also difficult to standardise and control16 and is commonly unavailable to practising physicians outside the major centres. Similar criticisms may be levelled at alternative glycosylated protein assays,4 which may be of considerable academic interest but are still unsuitable for widespread application in modern service laboratories.6 11 We present the fructosamine assay as a practical alternative measure of overall blood glucose control and the efficacy of insulin treatment in insulin dependent diabetics. The test is cheap and simple to perform using equipment available in most routine service laboratories.5 6 
SHORT REPORTS
High sensitivity assay of thyroid stimulating hormone in patients receiving thyroxine for primary hypothyroidism and thyroid carcinoma As thyroxine treatment often produces raised serum free thyroxine concentrations' we measured free thyroxine and thyroid stimulating hormone concentration in patients taking thyroxine for primary hypothyroidism and after ablative radioiodine treatment for thyroid carcinoma. We used an immunoradiometric assay for thyroid stimulating hormone that detects values below the lower limit of normal.
Patients, methods, and results
We studied 38 patients with primary hypothyroidism who were clinically euthyroid (34 women, four men; mean (SD) ages 60 (15) and 70 (3) years, Conversion: SI to traditional units-Thyroxine: I pmol/l 77 7 pg/100 ml. Triiodothyronine: I pmol/l_ 0Q65 pg/ml. respectively). Two had been treated with thyroxine for two months and the remainder for over a year. We also studied six patients with thyroid carcinoma (five women, one man, aged 45-77). They had received thyroxine for over a year.
We used Amerlex assays (Amersham Intemational) to measure free thyroxine (normal range 8-0-24-0 pmol/l (0-6-1-9 ng/100 ml)) and free triiodothyronine (normal range 3-0-7-5 pmol/l (2-0-4.9 pg/ml)) and Sucrosep immunoradiometric assay (Boots Ceiltech Diagnostics) to measure thyroid stimulating hormone (normal range 0-20-5-45 mU/l; typical limit of detection 0-07 mU/l).
Patients with hypothyroidism (figure)-Seven patients were taking 100 /g thyroxine daily and one 75 pg daily. Their mean (SD) free thyroxine and free triiodothyronine concentrations were 24-2 (2.3) and 5-3 (0-95) pmol (1.9 (0-2) ng/100 ml and 3-4 (0-6) pg/ml), respectively. Thyroid stimulating hormone was undetectable in four patients, concentrations in the other four being 0-5, 0 7, 2-9, and 4-2 mU/l. Eleven patients were taking 150 .g thyroxine daily. Their mean free thyroxine and free triiodothyronine concentrations were 26-7 (3-3) and 5-7 (1.0) pmol/l (2-1 (0 3) ng/100 ml and 3-7 (0-7) pg/ml), respectively. Thyroid stimulating hormone concentrations were undetectable in eight patients and 0-1, 0-2, and 0-9 mU/l in the remainder. Nineteen patients were taking 200 jug thyroxine daily. Their mean free thyroxine and free triiodothyronine concentrations were 26-3 (3.4) and (1-2) pmol/l (2-0 (0-3) ng/100 ml and 4'2 (0-8) pg/ml), respectively. Thyroid stimulating hormone concentrations were undetectable in 16 patients and 0-2, 0-3, and 1-2 mU/l in the remainder.
Patients with thyroid carcinoma (figure)-Five patients were receiving 200 ,&g and one 100 pg thyroxine daily. Their mean free thyroxine and free triiodothyronine concentrations were 32-1 (7.5) and 5*4 (1.8) pmol/l (2-5 (0.6) ng/100 ml and 3-5 (1-2) pg/ml), respectively. Thyroid stimulating hormone was undetectable in all patients.
Comment
These results confirm that thyroxine treatment in patients with hypothyroidism may result in raised free thyroxine and normal free triiodothyronine concentrationsl1and that most patients with primary hypothyroidism or thyroid carcinoma have subnormal thyroid stimulating hormone concentrations. The raised free thyroxine and subnormal thyroid stimulating hormone concentrations suggest that these patients had received too much replacement thyroxine and were subclinically hyperthyroid. It might be argued that because triiodothyronine is the hormone active at the level of the tissue the free triiodothyronine concentrations reflect the clinical state accurately.1 Patients receiving replacement thyroxine lack the thyroidal component of triiodothyronine in the plasma of normal subjects, so that their peripheral tissues must deiodinate enough plasma thyroxine into triiodothyronine to maintain euthyroidism. The pituitary, however, derives more of its nuclear triiodothyronine (which suppresses thyroid stimulating hormone) from circulating thyroxine than peripheral tissues do. The raised circulating thyroxine con-
